PortfoliosLab logoPortfoliosLab logo
PSTV vs. ARCC
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

PSTV vs. ARCC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Plus Therapeutics Inc (PSTV) and Ares Capital Corporation (ARCC). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, PSTV achieves a -68.14% return, which is significantly lower than ARCC's -6.83% return. Over the past 10 years, PSTV has underperformed ARCC with an annualized return of -68.14%, while ARCC has yielded a comparatively higher 12.46% annualized return.


PSTV

1D
2.51%
1M
-38.09%
YTD
-68.14%
6M
-70.27%
1Y
-11.45%
3Y*
-62.09%
5Y*
-67.02%
10Y*
-68.14%

ARCC

1D
0.28%
1M
-1.31%
YTD
-6.83%
6M
-5.38%
1Y
-8.17%
3Y*
9.59%
5Y*
8.14%
10Y*
12.46%
*Multi-year figures are annualized to reflect compound growth (CAGR)

PSTV vs. ARCC - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
PSTV
Plus Therapeutics Inc
-68.14%-55.45%-34.29%-63.19%-69.81%-48.02%-15.83%-83.45%-90.33%-80.13%
ARCC
Ares Capital Corporation
-6.83%1.07%19.78%20.03%-3.84%36.14%0.86%31.30%8.81%4.50%

Correlation

The correlation between PSTV and ARCC is 0.15, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.15

Correlation (3Y)
Calculated over the trailing 3-year period

0.12

Correlation (5Y)
Calculated over the trailing 5-year period

0.12

Correlation (10Y)
Calculated over the trailing 10-year period

0.11

Correlation (All Time)
Calculated using the full available price history since Oct 6, 2004

0.19

Fundamentals

Market Cap

PSTV:

$27.12M

ARCC:

$12.85B

EPS

PSTV:

-$4.87

ARCC:

$1.63

PS Ratio

PSTV:

2.41

ARCC:

4.79

PB Ratio

PSTV:

2.27

ARCC:

0.91

Total Revenue (TTM)

PSTV:

$4.15M

ARCC:

$2.63B

Gross Profit (TTM)

PSTV:

$3.89M

ARCC:

$1.86B

EBITDA (TTM)

PSTV:

-$1.39M

ARCC:

$2.05B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

PSTV vs. ARCC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PSTV
PSTV Risk / Return Rank: 4646
Overall Rank
PSTV Sharpe Ratio Rank: 3939
Sharpe Ratio Rank
PSTV Sortino Ratio Rank: 5757
Sortino Ratio Rank
PSTV Omega Ratio Rank: 5555
Omega Ratio Rank
PSTV Calmar Ratio Rank: 3939
Calmar Ratio Rank
PSTV Martin Ratio Rank: 3939
Martin Ratio Rank

ARCC
ARCC Risk / Return Rank: 2424
Overall Rank
ARCC Sharpe Ratio Rank: 2323
Sharpe Ratio Rank
ARCC Sortino Ratio Rank: 2121
Sortino Ratio Rank
ARCC Omega Ratio Rank: 2121
Omega Ratio Rank
ARCC Calmar Ratio Rank: 2828
Calmar Ratio Rank
ARCC Martin Ratio Rank: 2828
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PSTV vs. ARCC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Plus Therapeutics Inc (PSTV) and Ares Capital Corporation (ARCC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


PSTVARCCDifference
Sharpe ratioReturn per unit of total volatility

+0.36

Sortino ratioReturn per unit of downside risk

+1.57

Omega ratioGain probability vs. loss probability

1.13

0.94

+0.18

Calmar ratioReturn relative to maximum drawdown

-0.13

-0.42

+0.29

Martin ratioReturn relative to average drawdown

-0.21

-0.75

+0.54

PSTV vs. ARCC - Sharpe Ratio Comparison

The current PSTV Sharpe Ratio is -0.08, which is higher than the ARCC Sharpe Ratio of -0.44. The chart below compares the historical Sharpe Ratios of PSTV and ARCC, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

PSTV vs. ARCC - Drawdown Comparison

The maximum PSTV drawdown since its inception was -100.00%, which is greater than ARCC's maximum drawdown of -79.36%. Use the drawdown chart below to compare losses from any high point for PSTV and ARCC.


Loading charts...

Drawdown Indicators


PSTVARCCDifference

Max Drawdown

Largest peak-to-trough decline

-100.00%

-79.36%

-20.64%

Max Drawdown (1Y)

Largest decline over 1 year

-86.87%

-19.35%

-67.52%

Max Drawdown (3Y)

Largest decline over 3 years

-96.30%

-19.35%

-76.95%

Max Drawdown (5Y)

Largest decline over 5 years

-99.72%

-21.76%

-77.96%

Max Drawdown (10Y)

Largest decline over 10 years

-100.00%

-56.77%

-43.23%

Current Drawdown

Current decline from peak

-100.00%

-15.20%

-84.80%

Average Drawdown

Average peak-to-trough decline

-79.52%

-9.11%

-70.41%

Ulcer Index

Depth and duration of drawdowns from previous peaks

53.48%

10.89%

+42.59%

Volatility

PSTV vs. ARCC - Volatility Comparison

Plus Therapeutics Inc (PSTV) has a higher volatility of 17.29% compared to Ares Capital Corporation (ARCC) at 4.64%. This indicates that PSTV's price experiences larger fluctuations and is considered to be riskier than ARCC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


PSTVARCCDifference

Volatility (1M)

Calculated over the trailing 1-month period

17.29%

4.64%

+12.65%

Volatility (6M)

Calculated over the trailing 6-month period

87.33%

15.11%

+72.22%

Volatility (1Y)

Calculated over the trailing 1-year period

150.10%

18.65%

+131.45%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

198.10%

19.96%

+178.14%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

184.30%

25.60%

+158.70%

Dividends

PSTV vs. ARCC - Dividend Comparison

PSTV has not paid dividends to shareholders, while ARCC's dividend yield for the trailing twelve months is around 10.73%.


PositionTTM20252024202320222021202020192018201720162015
ARCC
Ares Capital Corporation
10.73%9.49%8.77%9.59%10.12%7.65%9.47%9.01%9.88%9.67%9.22%11.02%
PSTV
Plus Therapeutics Inc
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

PSTV vs. ARCC - Financials Comparison

This section allows you to compare key financial metrics between Plus Therapeutics Inc and Ares Capital Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00M202220232024202520260
763.00M
(PSTV) Total Revenue
(ARCC) Total Revenue
Values in USD except per share items

Frequently Asked Questions


PSTV and ARCC have a correlation of 0.15, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

PSTV has higher volatility (17.29%) compared to ARCC (4.64%). In terms of maximum drawdown, PSTV dropped -100.00% vs ARCC's -79.36%.

PSTV currently has the higher Sharpe Ratio (-0.08 vs -0.44), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for PSTV and ARCC

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer